Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07624981
Active, not recruiting Observational

Validation of Clinical Biomarkers Using Spatial Transcriptomics and Development of a Diagnostic Test to Characterize the Progression Potential of Cutaneous Precancerous Lesions

NCT07624981 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Régional Metz-Thionville
Phase
Observational
Started
2026-02-01
Last updated
2026-06-03

Condition(s) studied

Skin CancerDiagnostic

Study summary

Actinic keratoses are precancerous skin lesions that are the most common among all cancers and precancerous conditions in fair-skinned populations. The distinctive feature of these actinic keratoses is that some progress into skin cancers known as cutaneous carcinomas, while others regress spontaneously; currently, there is no way to distinguish between them, either through clinical observation or biological methods. The goal of the Diagno-KA project is to develop a diagnostic test that would distinguish between actinic keratoses that progress to cancer-so they can be surgically removed early (before they become severe and metastasize)-and those that regress, thereby avoiding unnecessary surgical intervention (to prevent scarring).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * patients with skin carcinomas and actinic keratoses Exclusion Criteria: * minor patient

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHR Metz-Thionville Metz France

More Centre Hospitalier Régional Metz-Thionville trials in France

Prognosis of Posterior Lamellar Keratoplasty Recruiting
Optical Characterization and Multi-modality, Multi-scale Modeling of Human Skin Applied to Cancer Diagnosis. Recruiting
Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae in a Geriatric Unit Recruiting
Referral of Patients With Biological Abnormalities to an Emergency Department Starting soon
Efficacy of Treadmill Walking With Hidden Vision for Rehabilitation in the Subacute Phase of Stroke Recruiting

Other trials for the same condition

Optical Characterization and Multi-modality, Multi-scale Modeling of Human Skin Applied to Cancer Diagnosis. Recruiting
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors Recruiting
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07624981 on ClinicalTrials.gov ↗ ← All trials in France